egads . Go to today's IPO NVTA or look at the wortld leader GHDX . This is a kangaroo stock.
A big bounce up ,but Go on , take the money and Run!
Invitae (NVTA) offices are down by the ballpark which is rapidly becoming another business investment hub of San Francisco ( and as recently #$%$ years ago was one of the worst parts of the city)
Randal W. Scott, Ph.D. 14.0%
Eric Aguiar, M.D. 15.2%
Baker Brothers Life Sciences, L.P. and affiliates 20.6%
BlackRock, Inc. 17.0%
Thomas, McNerney & Partners II, L.P. and affiliates 15.2%
Genomic Health, Inc. 9.0%
note: and if you want to add as I did you will pay at least 12 commissions for 2500 shares - ) Tradestation ))
added 2500 shares .First add in a very long time. GHDX profitable this year and the pieces are all in place.
Transcript from the Callxxxx://seekingalphaDOTcom/article/2904966-genomic-healths-ghdx-ceo-kim-popovits-on-q4-2014-results-earnings-call-transcript?part=single
Revenues 300 a yr and no debt.Do you know why its so cheap with regards to other stocks? Good Luck
not to spread speculation or anything - ) look at Foundations rev etc, Look at GHDX. Icahn always likes to say - we aint selling cheap - the Bakers never do.
Giant drug developer Roche, mastermind of four Bay Area deals over the past year, will make its next big play by buying a majority stake in Foundation Medicine for about $1.3 billion.
The Swiss-based parent of South San Francisco's Genentech Inc. said late Sunday night that it would buy about 15.6 million shares of Cambridge, Mass.-based Foundation Medicine (NASDAQ: FMI) — or roughly 56.3 percent — in a $780 million tender offer. That is a 109 percent premium over FMI's closing price on Friday.
Roche also will spend $250 million for 5 million newly issued shares.
What's more, Roche has gobbled up four other local companies in the past year, capped by its $8.3 billion deal in the fall for Brisbane drug developer InterMune Inc. It also bit off DNA sequencing system developer Genia Technologies Inc. of Mountain View in the summer for $350 million, Redwood City sequenc
LDT regulations approaching - Following the enactment of the
In early 2015, GHDX & SQNM are expected to receive separate NGS codes for their Oncotype Dx and MaterniT21 tests, which, for SQNM in particular, should help facilitate reimbursement timelines.
While we expect 2015 should bring major developments in the FDA’s move to implement
risk based LDT regulations, though we believe established players a la GHDX, MYGN,
SQNM should be well positioned to comply with any additional reporting burdens. The
FDA is in the process of conducting public workshops (Jan 8-9, 2015) to discuss its
proposed regulations of LDTs.
agree 100% . The Bakers are first and foremost M&A specialists who want to make money for their clients , like Stanford U - ) Good Luck
REDWOOD CITY, Calif., Sept. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its final guidance recommending Oncotype DX® as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone receptor-positive, invasive breast cancer. Consistent with leading international breast cancer treatment guidelines, including ASCO®, NCCN®, ESMO ® and St. Gallen, NICE's recommendation recognizes the unparalleled evidence of the clinical validity of the Oncotype DX test and its ability to enable physicians and their patients to make more informed, individualized decisions.
Additionally, recent data presented at major medical meetings showed clinically meaningful
differences between patient results generated by the Oncotype DX breast cancer test and the
Mammaprint test, which unlike Oncotype DX was developed using a largely untreated patient
population that did not reflect the established standard of care of hormone therapy for patients
with estrogen receptor positive disease. Specifically, these results revealed that patients
stratified as high-risk by Mammaprint with high ER expression may lead physicians to
inappropriately offer treatment with chemotherapy.
We realize there is a lot of information in the market right now that can lead to confusion, and
we encourage you to ask the following questions when talking to companies who claim to offer
tests similar to Oncotype DX.
• What specific clinical question was the test developed to answer and is it relevant
to current practice?
• Were multiple randomized studies, including treated and untreated patients,
conducted to validate and reproduce the test’s ability to answer this question?
• What comprises test volume – is it commercial or research use?
• Are they getting paid routinely by private payors without appeal?
• For tests in kit form, like the one Nanostring is developing, what measures are
taken to ensure high, reproducible quality at local labs?
• Have they conducted prospectively designed, randomized trials with long term
clinical outcomes (i.e., 10 years or longer)?
• What is the pipeline opportunity and how is the company investing in it to drive
As the field of molecular diagnostics advances and new companies offering genomic-based
breast cancer tests emerge, a number of you have approached us with questions about how
these efforts compare to Oncotype DX® and our work at Genomic Health. We’d like to take this
opportunity to highlight the important distinctions that should be taken into consideration as you
evaluate these companies and their products.
The Oncotype DX Recurrence Score® was developed to answer the specific question of which
estrogen receptor positive (ER+) breast cancer patients need chemotherapy in addition to
hormonal therapy. To validate it for this specific purpose, Genomic Health and its collaborators
obtained practice-changing results from landmark clinical studies that included patients
randomized to treatment (so that both prognosis and prediction could be obtained) and followed
for long term outcomes. To date, it is the only test validated to predict who benefits from
chemotherapy, and the only test included in all major breast cancer guidelines (ASCO,NCCN)
for treatment decision making. As a result, it has been broadly adopted by the physician
community, widely reimbursed in the United States, and used to guide treatment in more than
350,000 breast cancer patients around the world.
flatlander_ 60048 - the poster arikaycerocks is a clown following me around and taunting GHDX. Ignore it.
Genomic Health could be wildly profitable tomorrow if they didnt spend so much R& D money ( Felix oversees this branch of he co) . Ducks in a row to the max ,until they hand off the company.
Shire is working on its Messenger RNA and announced CFFT a non-profit drug discovery affiliate of the Cystic Fibrosis Foundation, will contribute up to $15 million to support Shire. Shire is investigating in therapies that could deliver mRNA direct to sites in the body, such as the lungs in the case of cystic fibrosis, where it can be used by the body's own cellular mechanism to produce normal working copies of the protein ( repost )
rtq- $37.74 but the volume is minuscule. So we did the ladder, Why they let it go now we will know soon....
of course not, you expect documentation?- ) This discussion was one I had with management. As I posted ,if GHDX can get rule changed that before you spend gazllions you get a genomic test, this stock will explode. You would think Insurance co's would be all over this so the resistance has to be very high . Good Luck